Clinical Trials Browser

Neoplasms, Unknown Primary

NCT00003526 2020-12-17

Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin

Phase 2 Terminated

8 enrolled 5 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT02966509 2018-10-31

EPAC

Phase NA Completed

213 enrolled 20 charts

CNSDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Colonic Neoplasms, Death, Glioblastoma, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Unknown Primary, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Testicular Neoplasms

NCT00066781 2017-04-04

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary

Phase 2 Completed

31 enrolled 8 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00936702 2017-03-21

Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary

Phase 2 Completed

46 enrolled 13 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00201734 2016-09-23

Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

Phase 1/2 Terminated

57 enrolled 11 charts

Tumor-Agnostic

Adenocarcinoma, Neoplasms, Neoplasms, Unknown Primary

NCT00360360 2013-12-04

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Phase 2 Completed

60 enrolled 6 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193609 2013-11-11

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Phase 2 Completed

48 enrolled 6 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193596 2013-05-03

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

Phase 3 Completed

198 enrolled 7 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

Clinical Trials

Sintilimab in Cancer of Unknown Primary

Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin

EPAC

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary

Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary

Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site